Form 8-K - Current report:
SEC Accession No. 0001193125-25-003248
Filing Date
2025-01-08
Accepted
2025-01-08 08:55:29
Documents
15
Period of Report
2025-01-08
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d874651d8k.htm   iXBRL 8-K 51700
2 EX-3.1 d874651dex31.htm EX-3.1 6302
3 EX-3.2 d874651dex32.htm EX-3.2 90037
  Complete submission text file 0001193125-25-003248.txt   310746

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA pstx-20250108.xsd EX-101.SCH 2837
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20250108_lab.xml EX-101.LAB 19481
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20250108_pre.xml EX-101.PRE 12144
17 EXTRACTED XBRL INSTANCE DOCUMENT d874651d8k_htm.xml XML 3984
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 25516692
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)